Literature DB >> 19410619

Glycan analysis in cell culture-based influenza vaccine production: influence of host cell line and virus strain on the glycosylation pattern of viral hemagglutinin.

Jana Schwarzer1, Erdmann Rapp, René Hennig, Yvonne Genzel, Ingo Jordan, Volker Sandig, Udo Reichl.   

Abstract

Mammalian cell culture processes are commonly used for production of recombinant glycoproteins, antibodies and viral vaccines. Since several years there is an increasing interest in cell culture-based influenza vaccine production to overcome limitations of egg-based production systems, to improve vaccine supply and to increase flexibility in vaccine manufacturing. With the switch of the production system several key questions concerning the possible impact of host cell lines on antigen quality, passage-dependent selection of certain viral phenotypes or changes in hemagglutinin (HA) conformation have to be addressed to guarantee safety and efficiency of vaccines. In contrast to the production of recombinant glycoproteins, comparatively little is known regarding glycosylation of HA, derived from mammalian cell cultures. Within this study, a capillary DNA-sequencer (based on CGE-LIF technology), was utilized for N-glycan analysis of three different influenza virus strains, which were replicated in six different cell lines. Detailed results concerning the influence of the host cell line on complexity and composition of the HA N-glycosylation pattern, are presented. Strong host cell but also virus type and subtype dependence of HA N-glycosylation was found. Clear differences were already observed, by N-glycan fingerprint comparison. Further structural investigations of the N-glycan pools revealed that host cell dependence of HA N-glycosylation was mainly related to minor variations of the (monomeric) constitution of single N-glycans. To some extent, shifts in the N-glycan pool composition regarding the proportion of different N-glycan types were observed. In contrast to this, a principal switch of the N-glycan type attached to HA was observed when comparing different virus types (A and B) and subtypes (H1N1 and H3N2).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19410619     DOI: 10.1016/j.vaccine.2009.04.076

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

1.  Chinese hamster ovary (CHO) host cell engineering to increase sialylation of recombinant therapeutic proteins by modulating sialyltransferase expression.

Authors:  Nan Lin; Joaquina Mascarenhas; Natalie R Sealover; Henry J George; Jeanne Brooks; Kevin J Kayser; Brian Gau; Isil Yasa; Parastoo Azadi; Stephanie Archer-Hartmann
Journal:  Biotechnol Prog       Date:  2015-03-01

2.  Vaccination with Killed but Metabolically Active E. coli Over-expressing Hemagglutinin Elicits Neutralizing Antibodies to H1N1 Swine Origin Influenza A Virus.

Authors:  Pei-Feng Liu; Yanhan Wang; Yu-Tsueng Liu; Chun-Ming Huang
Journal:  J Nat Sci       Date:  2017-02

3.  Molecular dynamics analysis of antibody recognition and escape by human H1N1 influenza hemagglutinin.

Authors:  Pek Ieong; Rommie E Amaro; Wilfred W Li
Journal:  Biophys J       Date:  2015-06-02       Impact factor: 4.033

4.  Site-specific glycosylation of the Newcastle disease virus haemagglutinin-neuraminidase.

Authors:  Cassandra L Pegg; Christine Hoogland; Jeffrey J Gorman
Journal:  Glycoconj J       Date:  2016-12-07       Impact factor: 2.916

5.  Animal Cell Expression Systems.

Authors:  M Butler; U Reichl
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

6.  State-of-the-Art Glycomics Technologies in Glycobiotechnology.

Authors:  Alexander Pralow; Samanta Cajic; Kathirvel Alagesan; Daniel Kolarich; Erdmann Rapp
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

7.  Impact of Protein Glycosylation on the Design of Viral Vaccines.

Authors:  Kathleen Schön; Bernd Lepenies; Guillaume Goyette-Desjardins
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

8.  Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus.

Authors:  Chia-Ying Wu; Yi-Chun Yeh; Yu-Chih Yang; Ching Chou; Ming-Tsan Liu; Ho-Sheng Wu; Jia-Tsrong Chan; Pei-Wen Hsiao
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

9.  Specific recognition of influenza A/H1N1/2009 antibodies in human serum: a simple virus-free ELISA method.

Authors:  Mario M Alvarez; Felipe López-Pacheco; José M Aguilar-Yañez; Roberto Portillo-Lara; Gonzalo I Mendoza-Ochoa; Sergio García-Echauri; Pamela Freiden; Stacey Schultz-Cherry; Manuel I Zertuche-Guerra; David Bulnes-Abundis; Johari Salgado-Gallegos; Leticia Elizondo-Montemayor; Martín Hernández-Torre
Journal:  PLoS One       Date:  2010-04-14       Impact factor: 3.240

10.  An influenza A/H1N1/2009 hemagglutinin vaccine produced in Escherichia coli.

Authors:  José M Aguilar-Yáñez; Roberto Portillo-Lara; Gonzalo I Mendoza-Ochoa; Sergio A García-Echauri; Felipe López-Pacheco; David Bulnes-Abundis; Johari Salgado-Gallegos; Itzel M Lara-Mayorga; Yenny Webb-Vargas; Felipe O León-Angel; Ramón E Rivero-Aranda; Yuriana Oropeza-Almazán; Guillermo M Ruiz-Palacios; Manuel I Zertuche-Guerra; Rebecca M DuBois; Stephen W White; Stacey Schultz-Cherry; Charles J Russell; Mario M Alvarez
Journal:  PLoS One       Date:  2010-07-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.